AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Company profile
Ticker
ABBV
Exchange
Website
CEO
Richard Gonzalez
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...
IRS number
320375147
ABBV stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-8
Registration of securities for employees
14 Aug 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
AbbVie Reports Second-Quarter 2024 Financial Results
25 Jul 24
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
3 Jul 24
25-NSE
Exchange delisting
3 Jun 24
SD
Conflict minerals disclosure
31 May 24
25-NSE
Exchange delisting
17 May 24
8-K/A
Departure of Directors or Certain Officers
8 May 24
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
AbbVie Reports First-Quarter 2024 Financial Results
26 Apr 24
Transcripts
ABBV
Earnings call transcript
2024 Q2
25 Jul 24
ABBV
Earnings call transcript
2024 Q1
26 Apr 24
ABBV
Earnings call transcript
2023 Q4
2 Feb 24
ABBV
Earnings call transcript
2023 Q3
27 Oct 23
ABBV
Earnings call transcript
2023 Q2
27 Jul 23
ABBV
Earnings call transcript
2023 Q2
27 Jul 23
ABBV
Earnings call transcript
2023 Q1
27 Apr 23
ABBV
Earnings call transcript
2022 Q4
9 Feb 23
ABBV
Earnings call transcript
2022 Q3
28 Oct 22
ABBV
Earnings call transcript
2022 Q2
29 Jul 22
Latest ownership filings
144
Notice of proposed sale of securities
8 Aug 24
4
RICHARD A GONZALEZ
7 Aug 24
144
Notice of proposed sale of securities
7 Aug 24
144
Notice of proposed sale of securities
5 Aug 24
4
RICHARD A GONZALEZ
19 Jul 24
144
Notice of proposed sale of securities
17 Jul 24
4
Susan E Quaggin
2 Jul 24
4
EDWARD J RAPP
2 Jul 24
4
Robert J Alpern
2 Jul 24
4
RICHARD A GONZALEZ
2 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.13 bn | 13.13 bn | 13.13 bn | 13.13 bn | 13.13 bn | 13.13 bn |
Cash burn (monthly) | 1.65 bn | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 3.76 bn | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 9.37 bn | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 5.7 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2024
71.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3208 |
Opened positions | 209 |
Closed positions | 181 |
Increased positions | 1368 |
Reduced positions | 1236 |
13F shares | Current |
---|---|
Total value | 207.28 tn |
Total shares | 1.26 bn |
Total puts | 9.65 mm |
Total calls | 12.98 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 170.66 mm | $29.27 tn |
BLK BlackRock | 136.43 mm | $23.40 tn |
STT State Street | 77.80 mm | $13.34 tn |
JPM JPMorgan Chase & Co. | 53.56 mm | $9.19 tn |
Capital International Investors | 38.60 mm | $6.62 tn |
MS Morgan Stanley | 37.24 mm | $6.39 tn |
Geode Capital Management | 36.68 mm | $6.28 tn |
Capital Research Global Investors | 33.19 mm | $5.69 tn |
Charles Schwab Investment Management | 24.97 mm | $4.28 tn |
Norges Bank | 22.48 mm | $3.86 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Aug 24 | Richard A Gonzalez | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 186.52 | 66,500 | 12.40 mm | 446,599 |
17 Jul 24 | Richard A Gonzalez | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 175 | 282,845 | 49.50 mm | 513,099 |
17 Jul 24 | Richard A Gonzalez | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 93.5 | 76,377 | 7.14 mm | 795,944 |
17 Jul 24 | Richard A Gonzalez | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 79.02 | 119,418 | 9.44 mm | 719,567 |
17 Jul 24 | Richard A Gonzalez | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 61.36 | 87,050 | 5.34 mm | 600,149 |
17 Jul 24 | Richard A Gonzalez | Option Common Stock | Option exercise | Dispose M | No | No | 93.5 | 76,377 | 7.14 mm | 152,755 |
17 Jul 24 | Richard A Gonzalez | Option Common Stock | Option exercise | Dispose M | No | No | 79.02 | 119,418 | 9.44 mm | 59,709 |
17 Jul 24 | Richard A Gonzalez | Option Common Stock | Option exercise | Dispose M | No | No | 61.36 | 87,050 | 5.34 mm | 0 |
30 Jun 24 | Alpern Robert J | Stock Equivalent Units Common Stock | Grant | Acquire A | No | No | 171.52 | 43 | 7.38 k | 9,541 |
30 Jun 24 | Susan E Quaggin | Stock Equivalent Units Common Stock | Grant | Acquire A | No | No | 171.52 | 87 | 14.92 k | 236 |
News
Peering Into AbbVie's Recent Short Interest
6 Sep 24
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
5 Sep 24
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
5 Sep 24
AbbVie Announces VRAYLAR Receives Reimbursement Recommendation From Canada's Drug Agency For Treatment Of Schizophrenia In Adults Following Successful Negotiations And LOI
4 Sep 24
10 Health Care Stocks With Whale Alerts In Today's Session
3 Sep 24
Press releases
AbbVie Declares Quarterly Dividend
6 Sep 24
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
4 Sep 24
iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs
4 Sep 24
AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases
27 Aug 24
SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator
27 Aug 24